For US-based MedTech and biopharma sponsors weighing first-in-human and early-phase strategies, the decision often comes down to two regions: Australia and Latin America. This guide compares regulatory pathways, timelines, costs, and CRO ecosystems so sponsors, founders, and investors can make an evidence-based call — with a clear emphasis on why Latin America increasingly wins for US sponsors targeting FDA-acceptable data at speed.
Regulatory Pathways: TGA vs LATAM Agencies
Australia’s CTN (Clinical Trial Notification) scheme via the TGA is well-known for a fast, notification-based start. But LATAM agencies have closed much of that gap for sponsors who structure submissions correctly. Colombia’s INVIMA can approve device studies in 90–120 days for well-prepared dossiers. Argentina’s ANMAT, Mexico’s COFEPRIS, Brazil’s ANVISA, and Peru’s DIGEMID each offer defined pathways with predictable review clocks — and crucially, all generate FDA-acceptable data under ICH-GCP.
Timelines to First-Patient-In
Australia’s headline advantage is study-start speed. But in practice, US sponsors running trials at Australian sites — via CROs like Novotech, George Clinical, Nucleus Network, Avance Clinical, CMAX, Linear Clinical Research, Southern Star, or Scientia Clinical Research — often lose weeks to ethics committee sequencing and time-zone friction with US sponsor teams. LATAM sites operating in US business hours, particularly in Colombia and Mexico, routinely match or beat Australian first-patient-in when the CRO owns both regulatory strategy and site activation.
Cost Structure and R&D Tax Incentives
Australia’s 43.5% R&D Tax Incentive is often the headline argument for running trials there. For eligible Australian-resident entities it is real value. But US sponsors need to evaluate the fully-loaded cost — site fees, per-patient costs, CRO fees, monitoring travel, currency exposure, and repatriation of tax benefits. LATAM per-patient costs typically run 30–50% below Australian rates, and USD-denominated contracts remove FX risk. For US sponsors who cannot structurally capture the AU tax benefit, LATAM delivers a lower absolute program cost.
FDA Acceptability of Foreign Clinical Data
Both Australian and LATAM data are accepted by the FDA under 21 CFR 312.120 (drugs) and 21 CFR 814.15 (devices), provided the study is conducted under ICH-GCP and the sponsor can document site qualifications, informed consent, and IRB/EC oversight. There is no regulatory advantage to Australian data over LATAM data at FDA. The differentiator is execution quality — which is a CRO selection question, not a geography question.
When Australia Wins, When LATAM Wins
Australia is the right call when: the sponsor is an Australian-resident entity capturing the R&D Tax Incentive; the indication requires a specific patient population concentrated in Australia; or the therapeutic area has deep site density unavailable elsewhere. Latin America is the right call when: the sponsor is US-based and needs FDA-acceptable data; per-patient cost and enrollment velocity matter; time-zone alignment with US sponsor teams is operationally important; or the target population maps well to LATAM demographics (cardiovascular, oncology, metabolic, infectious disease).
How bioaccess® Supports US Sponsors in LATAM
bioaccess® is a US–LATAM CRO purpose-built for MedTech, biopharma, and radiopharma sponsors who need FDA-acceptable early-phase data at LATAM cost structure and US time-zone alignment. We handle regulatory strategy across INVIMA, COFEPRIS, ANMAT, ANVISA, and DIGEMID; site activation across Colombia, Mexico, Argentina, Brazil, and Peru; and monitoring under ICH-GCP with US-standard documentation. Talk to us before you commit to Australia.